# Measles and rubella elimination country profile Norway



#### Measles elimination status

2016 eliminated 2017 eliminated

Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvo

#### Measles and rubella surveillance

National case-based surveillance for Lab confirmation for diagnosis of

Source: WHO/UNICEF Joint Reporting Form on Immunization, 2017

#### Measles and rubella immunization schedule, 2017

	Vaccine	Schedule	Year of introduction	
MCV1	MMR	15 months	MCV2	1983
MCV2	MMR	11 years RCV		1978
N	Yes			

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance

(http://www.who.int/immunization/monitoring\_surveillance/data/en/)
MMR = measles-mumps-rubella vaccine; MCVI = first dose measles-containing vaccine;

MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccir

### Definition used for an outbreak

Two or more cases, epidemiologically linked or laboratory confirmed with the same genotype, where at least on case is not imported



Source: Measles and rubella elimination Annual Status Update report, 2017



#### Rubella elimination status

2016 eliminated 2017 eliminated


Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvo

#### Demographic information, 2017

Total population	5 305 383
< 1 year old	61 868
< 5 years old	308 750

Source: World Population Prospects: The 2017 Revision, New York, United Nations

## Measles and rubella cases and immunization coverage, 2008-2017




Source: Disease incidence and immunization coverage (WUENIC), WHO, Data and Statistics,

Immunization Monitoring and Surveillance

(http://www.who.int/immunization/monitoring\_surveillance/data/en/) MCV1 = first dose of measles-containing vaccine

MCV2= second dose of measles-containing vaccine

# Confirmed measles cases by month of onset, 2013-2017




Source: CISID 2017

# Measles and rubella elimination country profile Norway




#### Measles cases by first subnational level, 2017



Source: Measles and rubella elimination Annual Status Update report, 2017

### Measles genotypes by first subnational level, 2017



Source: MeaNS 2017

Note: The dots in the maps are placed randomly within the administrative regions.

Map disclaimer: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

### Information on CRS, 2017



Source: Measles and rubella elimination Annual Status Update report, 2017 CRS = congenital rubella syndrome

#### Sources of infection, 2017

	Measles	Rubella
Imported	1	0
Import-related	0	0
Unknown/ Not reported	0	0
Endemic	0	0

Source: Measles and rubella elimination Annual Status Update report, 2017

## RVC comments, based on 2017 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Norway in 2017 and confirmed that measles and rubella elimination has been sustained.

Source:European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thrvc

# Measles and rubella elimination country profile Norway



## Measles incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected measles		Confirmed m	neasles cases		Discarded as	Measles	Genotypes detected	
	cases	Laboratory	Epi- linked	Clinically	Total	non- measles	incidence		
2013	47	8	0	0	8	39	1	D4,D8	
2014	43	3	0	0	3	40	0	D8	
2015	75	14	0	0	14	61	1.2	B3,D8	
2016	744	0	0	0	0	744	0	NA	
2017	757	1	0	0	1	756	0	D8	

Source: Measles and rubella elimination Annual Status Update report, 2013-2017

Incidence calculated per 1 million population ND = Data not available: NA= Not applicable

## Rubella incidence, epidemiologic and virologic characteristics, 2013-2017

	Suspected		Confirmed r	ubella cases		Discarded as	Rubella	Genotypes detected
	cases	Laboratory	Epi- linked	Clinically	Total	non- rubella		
2013	46	3	0	0	3	43	0	ND
2014	58	2	0	1	3	55	0	ND
2015	39	0	0	0	0	39	0	NA
2016	426	0	0	0	0	426	0	NA
2017	535	0	0	0	0	535	0	NA

Source: Measles and rubella elimination Annual Status Update report, 2013-2017

Incidence calculated per 1 million population ND = Data not available: NA= Not applicable

### Measles surveillance and laboratory performance indicators, 2013-2017

	Discarded non- measles rate	% 1st sub- national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for measles	% positive for measles	Rate of viral detection	% WHO and proficient labs
2013	83%	ND	ND	87.5%	ND	ND	62.5%	ND
2014	0.8	ND	100%	100%	43	7.0%	NA	ND
2015	1.2	ND	100%	86%	75	18.7%	100%	ND
2016	ND	100%	100%	NA	744	0%	NA	100%
2017	ND	100%	100%	100%	757	0.1%	100%	15.6%

ND = Data not available; NA= Not applicable

A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory

# Rubella surveillance and laboratory performance indicators,

	Discarded non- rubella rate	% 1st sub- national unit with ≥ 2 discarded cases	% cases with adequate laboratory investigtion	% origin of infection known	# specimen tested for rubella	% positive for rubella	Rate of viral detection	% WHO and proficient labs
2013	93.5%	ND	ND	100%	ND	ND	ND	ND
2014	1.1	ND	100%	100%	58	5.2%	ND	ND
2015	0.8	100%	100%	NA	39	0%	NA	ND
2016	ND	100%	100%	NA	426	0%	NA	100%
2017	ND	100%	100%	NA	535	0%	NA	13.5%

Source: AGC 2013-2017
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight
by a WHO accredited laboratory

#### Surveillance performance indicators and targets

- a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- b. % cases with adequate laboratory investigation: ≥ 80%
- c. % origin of infection known: ≥ 80%
- d. Rate of viral detection: ≥ 80%

